Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacological approach and adherence to treatment recommendations in frequently and non-frequently exacerbating COPD patients from Italy: MISTRAL - The prospective cohort, observational study.
Scalone G, Nava S, Ventrella F, Bussoli G, Catapano GA, Pennisi A, Dadduzio F, Schino P, Pela R, Bartezaghi M, Morini P, Porpiglia PA, Muscianisi E; Mistral study group. Scalone G, et al. Among authors: muscianisi e. Pulm Pharmacol Ther. 2018 Dec;53:68-77. doi: 10.1016/j.pupt.2018.09.001. Epub 2018 Sep 5. Pulm Pharmacol Ther. 2018. PMID: 30193866 Free article.
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY).
Bagel J, Blauvelt A, Nia J, Hashim P, Patekar M, de Vera A, Ahmad K, Paguet B, Xia S, Muscianisi E, Lebwohl M. Bagel J, et al. Among authors: muscianisi e. J Eur Acad Dermatol Venereol. 2021 Jan;35(1):135-142. doi: 10.1111/jdv.16558. Epub 2020 Jun 8. J Eur Acad Dermatol Venereol. 2021. PMID: 32365251 Free PMC article. Clinical Trial.
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results).
Bagel J, Nia J, Hashim PW, Patekar M, de Vera A, Hugot S, Sheng K, Xia S, Gilloteau I, Muscianisi E, Blauvelt A, Lebwohl M. Bagel J, et al. Among authors: muscianisi e. Dermatol Ther (Heidelb). 2018 Dec;8(4):571-579. doi: 10.1007/s13555-018-0265-y. Epub 2018 Oct 17. Dermatol Ther (Heidelb). 2018. PMID: 30334147 Free PMC article.
Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis.
Krueger JG, Murrell DF, Garcet S, Navrazhina K, Lee PC, Muscianisi E, Blauvelt A. Krueger JG, et al. Among authors: muscianisi e. J Allergy Clin Immunol. 2021 Mar;147(3):1107-1109.e2. doi: 10.1016/j.jaci.2020.09.021. Epub 2020 Sep 28. J Allergy Clin Immunol. 2021. PMID: 33002515 Free PMC article. Clinical Trial. No abstract available.
21 results